Skip to main content

Table 3 Secondary analysis 1—change in PSA pre-treatment to day 29

From: Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

Patient study ID

Early PSA

Day 29 PSA

1

15.08

12.14

2

14.5

16.52

3

3.98

4.4

4

5.98

5.96

5

4.32

2.7

6

10.52

14.43

7

5.26

4.61

8

5.16

6.09

  1. To determine the effectiveness of neoadjuvant rituximab in the treatment of prostate cancer as evaluated by the serum PSA
  2. Wilcoxon signed rank test, p-value = 0.84
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us